Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials
Ionizing radiation is frequently used to treat solid tumors, as it causes DNA damage and kill cancer cells. However, damaged DNA is repaired involving poly-(ADP-ribose) polymerase-1 (PARP-1) causing resistance to radiation therapy. Thus, PARP-1 represents an important target in multiple cancer types...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tech Science Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319588/ https://www.ncbi.nlm.nih.gov/pubmed/37415740 http://dx.doi.org/10.32604/or.2023.028310 |
_version_ | 1785068268501860352 |
---|---|
author | NAMBIAR, DHANYA K. MISHRA, DEEPALI SINGH, RANA P. |
author_facet | NAMBIAR, DHANYA K. MISHRA, DEEPALI SINGH, RANA P. |
author_sort | NAMBIAR, DHANYA K. |
collection | PubMed |
description | Ionizing radiation is frequently used to treat solid tumors, as it causes DNA damage and kill cancer cells. However, damaged DNA is repaired involving poly-(ADP-ribose) polymerase-1 (PARP-1) causing resistance to radiation therapy. Thus, PARP-1 represents an important target in multiple cancer types, including prostate cancer. PARP is a nuclear enzyme essential for single-strand DNA breaks repair. Inhibiting PARP-1 is lethal in a wide range of cancer cells that lack the homologous recombination repair (HR) pathway. This article provides a concise and simplified overview of the development of PARP inhibitors in the laboratory and their clinical applications. We focused on the use of PARP inhibitors in various cancers, including prostate cancer. We also discussed some of the underlying principles and challenges that may affect the clinical efficacy of PARP inhibitors. |
format | Online Article Text |
id | pubmed-10319588 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Tech Science Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-103195882023-07-06 Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials NAMBIAR, DHANYA K. MISHRA, DEEPALI SINGH, RANA P. Oncol Res Review Ionizing radiation is frequently used to treat solid tumors, as it causes DNA damage and kill cancer cells. However, damaged DNA is repaired involving poly-(ADP-ribose) polymerase-1 (PARP-1) causing resistance to radiation therapy. Thus, PARP-1 represents an important target in multiple cancer types, including prostate cancer. PARP is a nuclear enzyme essential for single-strand DNA breaks repair. Inhibiting PARP-1 is lethal in a wide range of cancer cells that lack the homologous recombination repair (HR) pathway. This article provides a concise and simplified overview of the development of PARP inhibitors in the laboratory and their clinical applications. We focused on the use of PARP inhibitors in various cancers, including prostate cancer. We also discussed some of the underlying principles and challenges that may affect the clinical efficacy of PARP inhibitors. Tech Science Press 2023-06-27 /pmc/articles/PMC10319588/ /pubmed/37415740 http://dx.doi.org/10.32604/or.2023.028310 Text en © 2023 Nambiar, Mishra and Singh https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review NAMBIAR, DHANYA K. MISHRA, DEEPALI SINGH, RANA P. Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials |
title | Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials |
title_full | Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials |
title_fullStr | Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials |
title_full_unstemmed | Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials |
title_short | Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials |
title_sort | targeting dna repair for cancer treatment: lessons from parp inhibitor trials |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319588/ https://www.ncbi.nlm.nih.gov/pubmed/37415740 http://dx.doi.org/10.32604/or.2023.028310 |
work_keys_str_mv | AT nambiardhanyak targetingdnarepairforcancertreatmentlessonsfromparpinhibitortrials AT mishradeepali targetingdnarepairforcancertreatmentlessonsfromparpinhibitortrials AT singhranap targetingdnarepairforcancertreatmentlessonsfromparpinhibitortrials |